Loading…

Preparation and characterization of superparamagnetic iron oxide nanoparticles stabilized by alginate

SPION with appropriate surface chemistry have been widely used experimentally for numerous in vivo applications. In this study, SPION stabilized by alginate (SPION-alginate) were prepared by a modified coprecipitation method. The structure, size, morphology, magnetic property and relaxivity of the S...

Full description

Saved in:
Bibliographic Details
Published in:International journal of pharmaceutics 2007-03, Vol.333 (1), p.177-186
Main Authors: Ma, Hui-li, Qi, Xian-rong, Maitani, Yoshie, Nagai, Tsuneji
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:SPION with appropriate surface chemistry have been widely used experimentally for numerous in vivo applications. In this study, SPION stabilized by alginate (SPION-alginate) were prepared by a modified coprecipitation method. The structure, size, morphology, magnetic property and relaxivity of the SPION-alginate were characterized systematically by means of XRD, TEM, ESEM, AFM, DLS, SQUID magnetometer and MRI, respectively, and the interaction between alginate and iron oxide (Fe 3O 4) was characterized by FT-IR and AFM. The results revealed that typical iron oxide nanoparticles were Fe 3O 4 with a core diameter of 5–10 nm and SPION-alginate had a hydrodynamic diameter of 193.8–483.2 nm. From the magnetization curve, the Ms of a suspension of SPION-alginate was 40 emu/g, corresponding to 73% of that of solid SPION-alginate. This high Ms may be due to the binding of Fe 3O 4 nanoparticles to alginate macromolecule strands as visually confirmed by AFM. SPION-alginate of several hundred nanometers was stable in size for 12 months at 4 °C. Moreover, T1 relaxivity and T2 relaxivity of SPION-alginate in saline (1.5 T, 20 °C) were 7.86 ± 0.20 s −1 mM −1 and 281.2 ± 26.4 s −1 mM −1, respectively.
ISSN:0378-5173
1873-3476
DOI:10.1016/j.ijpharm.2006.10.006